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The Use of Biochemical Assays in
Epidemiologic Studies of Reproduction
by Allen J. Wilcox,* Donna D. Baird,* Clarice R. Weinberg,*
E. Glenn Armstrong," Paul 1. Musey,§ Robert E.
Wehmann,"lf and Robert E. Canfield#
Recent progress in the assay ofurinary hormones has opened new opportunities for epidemiologists to
study hormones and health outcomes. This is especially true forstudies offemale reproduction. The cyclic
nature offemale reproduction can be fully described only by continuous frequent measurements that, in
ordertobepractical, requireeasilycollectedbiological specimens. Wedescribe ourexperience incollecting
and analyzing daily urine specimens from 301 healthy women. We conclude that this approach is notonly
feasible but potentially ofgreatvalue to epidemiologists forstudyingfertility, early pregnancy, the effects
oftoxic exposures on reproduction, and the relationships between reproduction and later risk ofchronic
diseases.
Introduction
Awoman's reproductive hormones affect notonlyher
ability to bear children, but also her eventual risk of
osteoporosis, cardiovasculardisease, breast cancer, and
other chronic diseases. This interplay of reproductive
hormones, pregnancy, and later illnesses is not easily
studied. For example, the risk of breast cancer in-
creases for women who have their first pregnancy after
age 25 (1). There may be a hormonal mechanism re-
sponsible for this association, but the pathway ofeffect
remains elusive despite recent progress (2,3).
Epidemiologists use data on the number and timing
ofbirths as an indirect measure offemale reproductive
fimction. Data on the occurrence of births are easily
available. Furthermore, pregnancyis animportanthor-
monal event in its own right. However, as a surrogate
for a woman's underlying hormone physiology, the
countingofbirths has limitations. Births are an expres-
sion not only of biological capacity but of sexual and
contraceptive practice. Also, births represent an un-
known fraction of all conceptions. Menstruation, ovu-
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lation, and conception are by comparison much more
direct measures ofa woman's reproductive physiology,
but these can be difficult (or impossible) to observe.
Actualreproductive hormone datafromhealthywomen
are scarce.
Advances in the technology of hormone assays are
opening new opportunities for epidemiologists to ob-
serve endocrine events. In this paper we describe our
experience in collecting daily urine specimens from
healthy women and assaying those urines for human
chorionic gonadotropin (hCG), human luteinizing hor-
mone (hLH), and the metabolic products of estradiol
and progesterone. We show thefeasibility ofusinghor-
moneassaystoreconstructthefollicular, ovulatory, and
luteal phases of the menstrual cycle and the events of
early pregnancy. These methods may prove useful not
only for understanding human conception and early de-
velopment, but also for studying the effects of toxins
on reproduction and for clarifying relations between a
woman's reproductive function and her later risk of
chronic diseases.
Collection of Daily Urine Specimens
Webeganin 1982torecruithealthywomenintostud-
ies that required collection ofdaily first-morning urine
specimens for up to 6 months. To our knowledge, no
onehadpreviouslyattempteddailyurinecollectionfrom
healthy volunteers over an extended period oftime.
Inordertomaximizecooperation, wearrangedtopick
up urine specimens at the volunteer's home on a sched-
ule convenient to her, usually every 1 or 2 weeks.WILCOX ETAL.
Womenwerefullyinfornedofthepurpose ofthestudies
and the importance ofdailyurine collection. Volunteers
were paid $10 a week for the collection and storage of
these specimens.
Women stored specimens in their home freezers.
Smallcoolers withblueice(refrigerantpacks)werepro-
vided to women for cold storage of specimens during
vacations or other times when volunteers did not have
access to a freezer. After pick-up, urines were kept
frozen at-20°C, exceptduringthawingforassays. Time
intervals between collection and analysis varied from a
few months up to 4 years.
Women were asked to make daily notes on a record
card at the time of each urine collection. Women indi-
cated whether specimen collection was from the first
morning void or later, and whether in the previous 24
hr there had been menstrual bleeding or sexual inter-
course.
Specimen bottles were 1-oz wide-mouth polypropyl-
ene jars with a screw-on lid. Eachjar was labeled with
the woman's identification number and date of collec-
tion. Urine jars were packed eight to a box. Two spec-
imens were collected on Mondaymornings, so that each
box represents 1 week ofurine collection. Our hormone
immunochemical assays require relatively small quan-
tities of urine, ranging from 4 mL for hCG to 0.4 mL
for steroids. Urine left over after analysis was trans-
ferred to borosilicate glass vials for long-term storage.
Human chorionic gonadotropin concentration rises
very rapidly during pregnancy, so that cross-contami-
nation from the urines of pregnant women to other
urines is athreat. Every effort was taken to avoid such
contamination; forexample, when womenreported that
they were pregnant, their boxes of urines were indi-
vidually stored in zip-lock plastic bags.
We collected daily specimens from a total of 301
women in three categories. Two hundred thirty women
wereenrolled atthetimetheydiscontinuedbirthcontrol
in ordertobecome pregnant (4). Fortywomencollected
urine while using intrauterine devices (IUDs) as their
method ofcontraception (5). Thirty-one women had had
tubal ligations for family planning reasons.
These groups of women differed somewhat in their
age, pregnancy experience, and education. However,
all groups were highly cooperative in collecting unne.
Only four women were not able to contribute adequate
urine or daily record card information and were there-
fore excluded. The remaining 297 women contributed
urines for 98% oftheir study-days in each ofthe three
categories. The percent of late voids (urines collected
later the same day) was 5% for women using no birth
control, 6% for women with tubal ligations, and 7%o for
women using IUDs.
In order to assess the importance of payments to
volunteers, we sent anonymous questionnaires to 80
current and pastparticipants. Seventywomenreturned
the questionnaires. Fifty-three said they probably
would not have volunteered forthe studies ifthere had
not been payment, and another 10 saidtheymight have
lost interest before the end of the study if there had
been no payment. Only seven women (10% of the re-
spondents) stated that payment did notencourage their
participation. Volunteersweremostlymiddle-class, col-
lege-educated women forwhom $10 aweekwas at most
a marginal contribution to family income. We believe
that payment helped establish the seriousness of the
study, and provided token compensation for the incon-
venience to which women were put on the study's be-
half. This is similar to conclusions from a study ofpay-
ment for mail questionnaires (6).
Urinary Measures of Female
Reproductive Hormones
Serum hormone levels are the most accurate reflec-
tion ofproduction formost hormones. Urinary levels of
a honnone (or its metabolic products) may be good in-
dicators ofendocrine production depending on patterns
of metabolism and excretion of the hormone and the
stability ofthe urinary products.
Among reproductive-age women, the production of
reproductive hornones is cyclic. Itisnecessarytomake
frequent measurements in order to describe the cyclic
production of these hornones accurately. One major
advantage ofurine assays over serum is in the ease of
frequent urine collection. Repeated blood sampling is
rarely feasible in field studies. Urine specimens offer a
furtheradvantageinthecaseofpituitaryhormonesthat
have pulsatile secretion: urine integrates serum levels
over a period oftime in a way that a single blood spec-
imen cannot.
Regularlyscheduleddailyurinecollectionreducesthe
effects ofdiurnal variation. For daily urine collections,
ascheduleoffirst-morningcollectionisperhapsthemost
convenient. First-morningcollections alsoarerelatively
more standard in theirconcentration than collections at
other times ofthe day, since there is presumably little
or no fluid intake by the volunteer during the night.
However, any once-a-day schedule of collection could
miss significant portions ofhormonesthat peakat other
times ofthe day, ifthose hormones are rapidly cleared.
Over the past 4 years we have performed more than
30,000 hormone assays in duplicate or triplicate using
nineradioimmuno-andimmunoradiometricassays. Sev-
eral of these assays have been carried out in the labo-
ratories of the investigators who developed them. As-
says for hCG have been performed at Columbia Uni-
versity, hLH assays atColumbiaand at LouisianaState
University, and steroid assays at Atlanta University.
Shipments to the laboratories were by overnight
freight, with specimens packed in dry ice.
The specific hormones that have been measured are
the estrogen metabolites estrone-3-glucuronide (E1G)
and estriol-16-a-glucuronide (E316G), the progesterone
metabolite pregnanediol-3-glucuronide (PdG), hLH
(three different assay methods), and hCG (three differ-
ent assay methods).
We will describe the laboratory methods for these
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assays, and then we will discuss the utility ofthe data
from each ofthese assays for epidemiologic studies.
Laboratory Methods
Assays ofE1G and E316G were carried out by direct
radioimmunoassay (RIA) procedures usingantisera de-
veloped in the Atlanta laboratory (7,8). The assay for
pregnanediol used an antiserum supplied through the
WHO Reagent MatchingProgram and adopted thegen-
eral methods described by Samarajeewa et al. (9).
Three assays for hLH were used, detecting various
combinations of intact hLH and hLH metabolic prod-
ucts. The first assay employed an RIA with Con A Se-
pharose extraction, as described by Wehmann et al.
(10). The two other assays used monoclonal antibody-
based two-site immunoradiometric assays (IRMA).
Methods for these assays are unpublished and so are
described in detail here. Assays were performed in Im-
mulon II microtiter plates with removable wells (Dy-
natech Inc.). Inorder to extract intacthLHfromurine,
monoclonal antibody A105 to the a subunit (11) was
adsorbed to the solid phase surface. In the other assay,
monoclonal antibody B201, produced againstfragments
ofthe 1 subunit of hCG and having strong cross-reac-
tivitywith free hLH 1 subunit and hLH a subunitfrag-
ments, was coated onto microtiter plate wells in con-
junctionwithA105. Thislatterassayformatisdescribed
as a total hLH IRMA and detects free hLH e and 13
fragments in addition to intact hLH. Solid phase-bound
hLH, hLH 1, and e fragments were detected utilizing
monoclonal antibody B105 labeled with 125I (11).
Microtiter plates for two-site IRMAs were prepared
as follows. Two hundred microliters of binding buffer
(0.2 M NaHCO3, pH 9.5) containing 5 ,ug A105 and 8
,ug B201 (total hLH assay), or 5 ,ug A105 only (intact
hLH assay), were added to each microtiter plate well
and incubated for 16 hr at 40C. Following removal of
the antibody solution, the wells were washed once with
deionized water. Subsequently, 200 ,uL of 1% BSA and
0.1% NaAzide in water were added and incubated at
room temperature for 4 hr to block excess antibody
binding sites. The blocking solution was removed, and
thewellswashedtwice withdeionizedwater. Microtiter
plates prepared in this manner could be stored without
significant loss ofbinding activity for up to 4 weeks at
40C.
Priorto assay, 1-mL aliquots ofurinespecimens were
adjusted to approximately pH 7.4 by the addition of0.1
mL of 1 M Tris-HCI, pH 9.0. The specimens were then
centrifuged at 2000 x g for 15 min at 40C. Assays were
started by the addition of 200 ,L aliquots of treated
urine specimensand standards induplicate tothe mono-
clonal antibody-coated wells. Standard preparations of
highlypurified, intacthLHandfreehLH 1 subunitwere
obtained from the National Pituitary Agency and dis-
solved in Buffer A (0.01 M NaHPO4, 0.15 M NaCl, 0.01
M EDTA, 0.1% NaAzide, and 0.1% bovine y-globulin,
pH 7.4). Microtiter plates were incubated at room tem-
perature for 24 hr. Specimens and standards were then
removedbyaspiration, andthewellswashedtwicewith
deionized water. Two hundred microliters of Buffer A
containing40,000'25I-B105wereaddedtoeachwell and
incubated at room temperature for 24 hr. Tracer anti-
body was then removed by aspiration, and the wells
washed five times with deionized water. Individual
wells were placed in 12 x 75-mm polystyrene tubes,
and the amount of radioactivity determined using a
PackardMultipriasgammacounter. Datareductionwas
performed automatically using a spline fit program.
Human chorionic gonadotropin was measured by
three methods. Two of the hCG assays used reagents
specific to the carboxyterminal peptide of the 1 chain:
an RIAsensitivetoabout0.40ng/mL (12) andan IRMA
sensitive to about 0.02 ng/mL (13). The third and least
sensitive assay is an RIA using the SB6 antibody, as
modified by Edmonds (14). A detailed comparison of
these three hCG assays has been previously published
(4).
Applicability for Epidemiologic
Studies
Figure 1 shows an example of several urinary hor-
mone profiles obtained from the urines of a healthy
woman who was trying to become pregnant. This
woman discontinued her birth controljust after a men-
ses, atwhich time she was enrolled and began to collect
urine. Menses during the study is indicated by the
shaded band.
Starting early in the first cycle, the top panel shows
agradual rise ofone ofthe estrogen metabolites (E1G),
reaching a peak in midcycle and then dropping. The
secondpanelshowsapeakofluteinizinghormoneduring
the same cycle, following the rise ofestrogen. Rupture
of the ovarian follicle typically occurs soon after the
midcycle surge ofhLH.
The third panel shows production of progesterone
duringthe luteal phase, when the ruptured ovarian fol-
licle is converted to a corpus luteum. The fourth panel
shows hCGresults; no hCG was found in thefirst cycle.
The bottom panel shows days ofintercourse. No inter-
course occurred during this cycle from the third day
before the hLH peak through the third day after.
Inthesecondcycle, thehormoneeventsarerepeated.
In contrast to the earlier cycle, there was intercourse
on the 2 days before and afterthe hLH peak. This cycle
resulted in successful conception and pregnancy, as sig-
nalled by the abrupt rise in hCG (fourth panel). This
pregnancy ended with delivery ofa healthy girl.
As a selected example, this figure illustrates the de-
scriptive powerofhormone profilesincombination with
menstrual andintercoursedata. However, thepotential
value of these assays for epidemiologic studies is not
found in selected examples, but rather in their appli-
cability to large groups of women. For example, an
assaythatprovidesinterpretabledataforonlyafraction
of women would probably not be suitable for epidemi-
ologic studies, even ifthe data were very clear for par-
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FIGURE 1. Multipleurinaryhormoneprofflesfor ahealthy womanattempting pregnancy. (Shadedportionindicatesdaysofmenstrualbleeding;
menses accompanying the first cycle was finished when the volunteer entered the study.)
ticular women. In the following section we discuss the
usefulness of urinary hormone measurements for field
studies.
Estrogen and the Urinary Metabolites
Natural estrogens comprise a diverse family of sim-
ilarly acting hormones. These hormones are produced
andmetabolized by manydifferentpathwaysthatwould
notbe well summarized in asingle measure ofestrogen.
In nonpregnant women ofreproductive age, the ovary
is the major source of estrogens. Estrogens also are
produced by the adrenals and by peripheral conversion
ofandrogens, particularly in fat tissue. Circulating es-
trogens include estrone, estriol, and estradiol, which is
the most potent.
Estrogens aremetabolized inseveraldifferenttissues
(most importantly the liver, but also the intestine, kid-
ney, brain, and blood) to catechol estrogens, glucuro-
nides, and sulfates. Metabolized estrogen is excreted in
feces, saliva, and sweat, as well as in urine. Some of
the conjugated metabolites enter the gut via the bile,
are converted back to free or active estrogens by gut
bacteria, and then are reabsorbed into the circulation.
This enterohepatic-biliary circulation can have large ef-
fects on the levels of serum estrogens, so that neither
serum nor urinary estrogen levels are direct quantita-
tive measures of ovarian production. The use of anti-
biotics, for example, can profoundly affect serum and
urine levels ofthe estrogen metabolites by altering in-
testinal bacteria.
Several estrogen metabolites are measurable in
urine, including glucuronides of estrone, estradiol and
estriol, and the catechol estrogens. In most women,
over half of the urinary estrogen is in the form of ca-
techol estrogen metabolites. These metabolites are rel-
atively unstable, and urine must be acidified after col-
lection in order to preserve the metabolites for assay.
The next most abundant urinary estrogen metabolite
is E1G, which correlates well with serum levels of es-
tradiol (the chief ovarian estrogen). The glucuronide
estrogen metabolites are more stable and are reliably
measured in urines collected with no special prepara-
tion. E1G is the most studied urinary estrogen and pro-
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vides a useful measure ofovarian function (15,16). The
one additional metabolite thatwe have assayed, E316G,
behaves very similarly to estrone glucuronide.
In general, estrogen patterns are similar within
womenbut canvaryconsiderablybetweenwomen. This
variability may reflect differences in production, me-
tabolism, diet, medication, or other characteristics of
the women.
Progesterone and Its Urinary Metabolite
Progesterone is the major hormone product of the
corpus luteum. The small amount ofprogesterone made
by the adrenals is negligible, so that serum levels of
progesterone canbeused asameasure ofcorpusluteum
function. Low progesterone levels in the luteal phase
of the cycle are clinically used to identify anovulatory
cycles.
Themajormetabolic product ofprogesterone is preg-
nanediolglucuronide, which is excreted inurine. Serum
progesterone and urinary pregnanediol glucuronide are
highly correlated, which makes the urinary measure
very useful (17). The first cycle in Figure 1 shows the
luteal phase increase of progesterone after ovulation,
and a decline just before onset ofmenses.
The ratio ofurinary E1G to pregnanediol glucuronide
has been used to identify a midcycle day close to the
day ofhLH peak(18). Arapid decline oftheratiomarks
the time immediately after the estrogen peak, when
estrogen is falling and progesterone is rising. This ste-
roid surrogate for the ovulatory phase ofthe menstrual
cycle is dependably found in all but a few ovulatory
cycles.
Luteinizing Hormone (hLH)
Luteinizinghormoneandfollicle-stimulatinghormone
(FSH) are complex glycoprotein hormones produced by
the pituitary gland. These hormones surge at midcycle
inresponse to agonadotropinreleasinghormone surge,
which in turn is triggered by rising follicular estrogen.
In the absence ofassays for urinary FSH, we consider
HUMAN
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only hLH in detail here. The hLH surge stimulates the
rupture and luteinization of the ovarian follicle. Ovu-
lation usually follows hLH surge within24to 56 hr(19).
ThemeandurationofthehLHsurgehasbeenestimated
to be about 48 hr (20), but there may be considerable
variability. HLH is rapidly metabolized and excreted;
its serum half-life is less than 2 hr. We used three mea-
sures ofurinary hLH and its metabolites in an effort to
detect the hLH surge reliably, but without great suc-
cess.
We measured daily urinary hLH in 89 cycles with an
RIAthatdetectsintacthLHandmetabolites, 109cycles
with an IRMA for intact hLH, and 72 cycles with an
IRMA that detects free hLH p-subunit and its frag-
ments as well as intact hLH. Results were similar in
everycase: AreasonablyclearhLHsurgecouldbeiden-
tified in 68 to 74% ofthe cycles. Intheremainder, there
was more than one surge, an ill-defined surge, or no
surge at all. The proportion ofcycleslackingadefinable
hLH surge was similar whether looking within cycles
ofindividual women or across all women.
WebelievethatourhLH assays aremissingrealmid-
cyclesurges. MostofthecycleswithnoclearhLHsurge
have patterns of estrogen rise and fall with progester-
one rise that suggest the occurrence of normal ovula-
tion. Six babies were conceived in cycles that had no
apparent rise in urinary hLH with one or more assays,
further evidence that real hLH events were missed.
There are several reasons why we could be missing
hLH surges in our urines. Perhaps most likely, an hLH
surge that lasts for less than 24 hr could be undetected
when samples are collected only once a day, or at the
wrong time ofday. Edwards recently reported data that
show a tendency for the LH surge to begin between 7
a.m. and noon (21). Corsonfoundthatthe hLH surgewas
detectable in 56% ofcycles when urine was collected be-
tween 5 A.M. and 8 A.M., and in 94% when urines were
collected between 11 A.M. and 3 P.M. (22). These data
suggest that first-morning unne may be poorly timed for
optimum detection ofthe hLH surge ofovulation.
AsecondpossibilityisthathLHisexcretedintourine
in many fragments, and our assays may not have broad
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FIGURE 2. Urinary hCG proffle for a healthy woman attempting pregnancy, indicating subclinical pregnancy loss followed by clinically
recognized pregnancy.
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enough specificity to detect certain varieties of hLH
products. Thirdly, even though we are missingonly 2%
of urine specimens, it is probable that a few of those
missing specimens fell on the day ofthe hLH surge.
The hLH assay methods we have evaluated using
first-morningurineshavenotbeenparticularlypractical
from an epidemiologic point ofview. Each ofthe assays
fails to provide an indication ofthe ovulatory phase for
at least a quarter ofall cycles. Assays for hLH in first-
morning urines have not been highly successful else-
where either, although this is not necessarily apparent
in the literature. Published data on urinary hLH are
sometimes based on selected cycles (often not explicitly
stated), or averaged over a number of cycles, which
obscures the variability among cycles. The issues of
urinary hLH measurement, including timing of speci-
men collection, deserve more study.
Human Chorionic Gonadotropin
Human chorionic gonadotropin (hCG) belongs to the
family ofglycoprotein hormones that includes hLH and
FSH. Unlike the other glycoproteins, however, hCG is
customarily produced not by the pituitary but by the
trophoblastic cells of the blastocyst. Thus, hCG is a
measure ofpregnancy and isthe mostreliable and thor-
oughly researched of the biochemical pregnancy mea-
sures.
Human chorionic gonadotropin and hLH are struc-
turally similar and act at the same receptor site. This
similarity has made it difficult to measure very small
quantities of hCG in the presence of hLH. Although
several hCG assays have been regarded as ,-chain spe-
cific, it is only since the development ofantibodies spe-
cific to the unique carboxyterminal peptide ofthe hCG
,3 chain that highly specific hCG assays have been pos-
sible (13).
Concentrations of hCG in urine and blood are ap-
proximately the same (23). hCG is excreted in urine
largely in its intact form, and is extremely stable. In a
conception cycle, urinary hCG is first detectable about
7 to 10 days after ovulation, near the time of implan-
tation, and several days before the expected onset of
menses.
The chemical detection ofpregnancybefore the preg-
nancyisotherwiseapparentmakesitpossible toidentify
clinically unrecognized pregnancy losses. Figure 2
shows an unrecognized pregnancy loss in the second
cycle, followed in the third cycle by successful concep-
tion and eventual delivery of a healthy girl.
It is essential in studies of early pregnancy loss to
use an hCG assay with adequate sensitivity and speci-
ficity. Problems with sensitivity and specificity ofhCG
assays have contributed to inconsistent findings in the
literature concerning the frequency ofclinically unrec-
ognized pregnancy losses (14,24,25). Those studies did
not collect daily specimens and used assays that are
susceptible to cross-reaction with hLH. Furthermore,
the assaysused are too insensitive to detect most ofthe
early pregnancy losses identified by the IRMA (4).
Summary
We have described our experience with the mea-
surement of urinary reproductive hormones in epide-
miological studies. We find that it is practical to collect
daily urine specimens from healthy volunteers. We also
find thatthe hormone events ofthemenstrual cycle and
earlypregnancyarereliablymeasuredbyassaysoffirst-
morning urine specimens, with the notable exception of
themidcycle hLHsurge. Theestrogen/progesteronera-
tio may be an adequate surrogate in such samples for
detection ofthe ovulatory phase.
Technical advances in the assay ofreproductive hor-
mones will undoubtedly continue. Prospective studies
of female reproductive physiology are now possible on
a large scale, and will become increasingly practical.
Such studies should be able to provide valuable insights
in many areas ofepidemiologic research, including the
biology offertility and early pregnancy, the sensitivity
of reproductive function to disruption by occupational
and other environmental hazards, and the relation of
reproductive function to eventual risk of chronic dis-
ease.
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